Rêgo Daniela Fortunato, Elias Silvia Taveira, Amato AngéLica Amorim, Canto Graziela De Luca, Guerra Eliete Neves Silva
Laboratory of Oral Histopathology, School of Health Sciences, University of Brasília, Brasília 70843-080, Brazil.
Laboratory of Molecular Pharmacology, Department of Pharmaceutical Sciences, School of Health Sciences, University of Brasília, Brasília 70919-970, Brazil.
Oncol Lett. 2017 Feb;13(2):554-566. doi: 10.3892/ol.2016.5526. Epub 2016 Dec 20.
Metformin is commonly used for treating type 2 diabetes, and may also reduce cancer risk. Previous studies have demonstrated the association between metformin use and a decreased risk of head and neck cancer. Therefore, the aim of the present systematic review was to summarize the available literature on the anti-tumor effects of metformin on head and neck squamous cell carcinoma (HNSCC). Research studies were obtained from Cochrane Library, Embase, LILACS, MEDLINE and PubMed databases, without time or language restrictions. Only studies analyzing the effects of metformin on HNSCC cell lines were included. The authors methodically appraised all the selected studies according to the Grading of Recommendations Assessment, Development and Evaluation method to make a judgment of the evidence quality. Of the 388 identified reports, 11 studies met the inclusion criteria and were used for qualitative analysis. These studies demonstrated that metformin is important in inhibiting cell proliferation, inducing G0/G1 cell cycle arrest and apoptosis, and in regulating proteins involved in carcinogenesis pathways, which corroborates its potential anti-tumor effects. The present systematic review highlights the biological mechanisms of metformin used alone or together with traditional therapies for cancer. Though very limited, currently available preclinical evidence shows that metformin exerts a potential effect on head and neck carcinoma.
二甲双胍常用于治疗2型糖尿病，也可能降低癌症风险。先前的研究已证实二甲双胍的使用与头颈癌风险降低之间存在关联。因此，本系统评价的目的是总结关于二甲双胍对头颈鳞状细胞癌（HNSCC）抗肿瘤作用的现有文献。研究报告来自Cochrane图书馆、Embase、LILACS、MEDLINE和PubMed数据库，无时间或语言限制。仅纳入分析二甲双胍对HNSCC细胞系作用的研究。作者根据推荐分级评估、制定和评价方法对所有选定研究进行系统评价，以判断证据质量。在388篇已识别的报告中，11项研究符合纳入标准并用于定性分析。这些研究表明，二甲双胍在抑制细胞增殖、诱导G0/G1期细胞周期阻滞和凋亡以及调节致癌途径相关蛋白方面具有重要作用，这证实了其潜在的抗肿瘤作用。本系统评价强调了二甲双胍单独或与传统癌症治疗联合使用的生物学机制。尽管目前可用的临床前证据非常有限，但表明二甲双胍对头颈癌具有潜在作用。
